{
    "nct_id": "NCT05568550",
    "official_title": "Phase II Study of Pembrolizumab in Combination With Radiation With or Without Olaparib in Localized High-risk Prostate Cancer",
    "inclusion_criteria": "* Male participants with histologically confirmed adenocarcinoma of the prostate\n* High-risk / very high-risk status per NCCN guidelines\n* ECOG performance status 0 to 1\n* No pelvic nodes >2 cm in long axis as established by CT imaging\n* Agree to use contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Adequate organ and marrow function\n* Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is â‰¤90 days prior to the date of registration\n* Prior 5-alpha reductase inhibitor (for example, finasteride) for prostatic hypertrophy is allowed if discontinued at least 60 days prior to registration.\n* Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* PSA > 150ng/ml\n* Prior hormonal therapy with LHRH agonists (e.g., Lupron) and LHRH antagonists (e.g., Degarelix)for prostate cancer continuously for more than 90-days prior to study enrollment.\n* Prior radiation to the prostate. Previous pelvic RT or major surgery (colorectal anastomosis, total cystectomy, radical prostatectomy, TURP, etc.). History of Ulcerative proctitis.\n* Concurrent active, additional malignancy in the last 2 years.\n* Prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization.\n* Patients with distant metastases",
    "miscellaneous_criteria": ""
}